Navigation Links
OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
Date:2/6/2013

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City, on Tuesday, February 12th at 3:00PM Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies.  This year's conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. To find out more information on the event, visit http://www.bio.org/events/conferences/bio-ceo-investor-conference

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. 


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
2. OncoSec Medical Announces $7.2 Million Public Offering
3. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
4. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
5. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
6. OncoSec to Present at Upcoming Healthcare and Investor Conferences
7. OncoSec Granted New Patent from China
8. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
11. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
Breaking Medicine Technology:
(Date:7/24/2017)... MA (PRWEB) , ... July 24, 2017 , ... Every ... an invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic ... level with a James Bond theme, Mission: InstructureCon 0017. , To extend their ...
(Date:7/24/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... to expand its solution to help government contractors more quickly and cost-effectively comply with ... address the authentication requirements within NIST SP800-171, but no matter how you address ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
(Date:7/24/2017)... ... July 24, 2017 , ... Independence Blue Cross ... on an Innovation Collaboration program, have signed a five-year agreement that will marshal ... the care members and patients receive. The agreement also signifies Jefferson Health officially ...
(Date:7/24/2017)... ... ... CDC study shows that, although people are taking more steps to protect themselves from sunburn, ... one case of sunburn within the past year. It’s common and people have been dealing ... only recently have people become conscientious of the risks that accompany sunburns. , The team ...
Breaking Medicine News(10 mins):